STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 249,503 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 249,503 shares of the stock in a transaction dated Monday, March 3rd. The stock was acquired at an average cost of $16.64 per share, with a total value of $4,151,729.92. Following the transaction, the insider now directly owns 11,953,198 shares in the company, valued at approximately $198,901,214.72. This trade represents a 2.13 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, February 27th, Broadwood Partners, L.P. acquired 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.46 per share, with a total value of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The stock was purchased at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The stock was purchased at an average cost of $24.24 per share, for a total transaction of $1,296,840.00.

STAAR Surgical Stock Down 5.9 %

Shares of NASDAQ:STAA traded down $1.03 during trading on Monday, hitting $16.47. The stock had a trading volume of 1,350,529 shares, compared to its average volume of 1,112,576. The stock has a 50-day simple moving average of $21.55 and a two-hundred day simple moving average of $27.18. The stock has a market capitalization of $812.38 million, a price-to-earnings ratio of -40.17 and a beta of 0.62. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the period. HighTower Advisors LLC purchased a new stake in STAAR Surgical in the third quarter valued at $336,000. Polar Asset Management Partners Inc. grew its position in STAAR Surgical by 44.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock worth $6,271,000 after purchasing an additional 51,800 shares during the period. JPMorgan Chase & Co. raised its stake in shares of STAAR Surgical by 411.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after buying an additional 172,779 shares during the last quarter. Finally, Defender Capital LLC. lifted its holdings in shares of STAAR Surgical by 3.5% in the 4th quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock valued at $17,041,000 after buying an additional 23,950 shares during the period. 96.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent analyst reports. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Mizuho cut STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $45.00 to $17.00 in a research report on Wednesday, February 12th. Stephens reissued an “equal weight” rating and issued a $28.00 price target on shares of STAAR Surgical in a report on Wednesday, February 12th. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $26.86.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.